康弘药业：康柏西普眼用注射液收到临床试验补充申请批准通知书

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology Co., has received approval from the National Medical Products Administration for the clinical trial supplement application of Kangbaxip (Kangbaxip eye injection) [1] Group 1: Product Development - Kangbaxip is a class 1 biopharmaceutical innovation drug developed independently by Kanghong Biotechnology, possessing complete intellectual property rights [1] - The drug effectively binds with VEGF in blood and tissues, blocking the signaling pathways that promote neovascularization and growth [1] Group 2: Clinical Application - The current approval marks an exploration of high-dose Kangbaxip eye injection in clinical applications, which is expected to enhance patient medication adherence and reduce medical burden [1]